机构：[1]Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.其他科室肿瘤科中山大学附属第一医院[2]Sun Yatsen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.其他部门华南肿瘤学国家重点实验室中山大学肿瘤防治中心[3]Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.[4]Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.[5]Department of Extracorporeal Circulation, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.心血管医学部体外循环科中山大学附属第一医院[6]Department of Surgical Laboratory, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.外科科室外科实验中心中山大学附属第一医院[7]Department of Ultrasound, Cancer Center, Sun Yat- Sen University, Guangzhou, 510060, China.
Inosine monophosphate dehydrogenase type II (IMPDH2) has been shown to play critical roles in the development and progression of several human cancers. However, little is known about IMPDH2 expression and its clinical significance in nasopharyngeal carcinoma (NPC). Western blotting, qRTPCR and immunohistochemistry were employed to evaluate IMPDH2 expression in NPC cell lines and tissues. In our study, elevated expression of IMPDH2 was observed at both the protein and mRNA levels in NPC cell lines than in NPEC2 Bmi-1. IMPDH2 protein expression was markedly higher in NPC tissues than in adjacent non-tumorous tissues. Moreover, IMPDH2 expression in NPC correlated with several clinicopathological parameters, including T classification (P = 0.023), TNM stage (P = 0.020), distant metastasis (P = 0.001) and death (P = 0.002). Further Cox regression analysis suggested that IMPDH2 expression was an independent prognostic factor for overall survival (P = 0.001) and diseasefree survival (P < 0.001). In addition, stratified survival analysis showed that high expression of IMPDH2 could be a prognostic factor for NPC patients with TNM stage I/II (OS: P = 0.012; DMFS: P = 0.007), TNM stage III/IV (OS: P = 0.028; DMFS: P = 0.020). Our study demonstrates IMPDH2 may be served as an independent prognostic biomarker for NPC patients, in which high IMPDH expression suggests poor prognosis of NPC patients.
基金：
Nature Science Foundation of China [81401991]; Science and Technology Foundation of Guangdong Province, China [2014A020212143]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|3 区综合性期刊
小类|3 区综合性期刊
最新[2023]版：
大类|2 区综合性期刊
小类|2 区综合性期刊
第一作者：
第一作者机构：[1]Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.[2]Sun Yatsen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.[2]Sun Yatsen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
推荐引用方式(GB/T 7714)：
Yi Xu,Zhousan Zheng,Ying Gao,et al.High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma[J].SCIENTIFIC REPORTS.2017,7(1):-.doi:10.1038/s41598-017-00887-1.
APA：
Yi Xu,Zhousan Zheng,Ying Gao,Shiyu Duan,Cui Chen...&Jiaxing Zhang.(2017).High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma.SCIENTIFIC REPORTS,7,(1)
MLA：
Yi Xu,et al."High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma".SCIENTIFIC REPORTS 7..1(2017):-
